A combination of lncRNAs and its model for diagnosing gliomas
By detecting the expression levels of six lncRNAs in human peripheral blood, a multi-molecular biomarker model was constructed, which solved the problem of inaccurate prognostic evaluation of glioma in existing technologies and achieved higher predictive accuracy and patient risk grouping capabilities.
CN115198021BActive Publication Date: 2026-05-26ZHONGNAN HOSPITAL OF WUHAN UNIV
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- ZHONGNAN HOSPITAL OF WUHAN UNIV
- Filing Date
- 2022-08-23
- Publication Date
- 2026-05-26
Smart Images
Figure CN115198021B_ABST
Abstract
This invention discloses an oligonucleotide probe combination for detecting the expression levels of six lncRNAs in human peripheral blood. The six lncRNAs are C1RL-AS1, LINC00968, MIR155HG, CPB2-AS1, LINC00906, and WDR11-AS1. Detecting the expression levels of these six key lncRNAs in human peripheral blood using this probe combination can predict the prognosis of glioma patients. This invention provides a new method for the clinical diagnosis of gliomas and has significant clinical value and promising prospects for widespread application.
Need to check novelty before this filing date? Find Prior Art